REDMOND, WA, – Micronics, Inc., today announced that it has been awarded a Small Business Technology Transfer grant totaling approximately $440,000 to develop a rapid method for nucleic acid detection of known and emerging respiratory infections. The grant advances the combined use of two novel platforms for molecular diagnosis of these pathogens at low level and in a point of care test format.

The grant entails a collaborative effort between researchers at Micronics and the Seattle Children’s Research Institute (SCRI), in which a novel primer design method that enables detection of distantly related gene sequences will be used with Micronics microfluidic molecular diagnostic test platform. The PCR amplification method was developed by SCRI’s Dr. Timothy Rose and colleagues and involves a unique technology known as consensus-degenerate hybrid oligonucleotide primer method, or CODEHOP.

CODEHOP makes it possible to target conserved sequences within a pathogen family in order to identify both known and unknown variants of a disease pathogen. Using CODEHOP-generated sequences, Micronics will develop an integrated, microfluidics-based system for detection of specific respiratory disease infections. Micronics platform reduces the volume of reagent and sample required to perform nucleic acid amplification and the overall cost and time to obtain a result. The combined platform will permit rapid, near patient diagnosis of a range of pathogenic respiratory viruses, including emerging respiratory viruses.

The emergence of several new respiratory viruses, including the recent H1N1 swine flu, has raised awareness that viruses continuously evolve and emerging viruses have the potential to produce global pandemics. This emphasizes the need for a molecular diagnostic approach that is capable of accurately detecting new or variant viruses. Comprehensive virus sequence arrays exist, but these tests are expensive, limited to known sequences, have limited sensitivity and are not intended for point-of-care use.

Current multiplexed nucleic acid amplification assays and culture-based diagnostic tests in use today fail to detect viral pathogens in over 50% of samples obtained from individuals who have respiratory disease. A likely explanation for this is that there are unknown or conserved sequencevariant viruses that these current tests miss. Precise and timely diagnosis of the etiological agent that is causing respiratory symptoms is critical in order to distinguish between viral and bacterial infection for optimal medical intervention and patient care.

Grant funding for this effort is from the National Institute of Allergy and Infectious Diseases under the National Institutes of Health (NIH); award number 1R43 AI084851-01. The content of this release is solely the responsibility of Micronics and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

About Micronics

Micronics, Inc. is advancing a family of point of care tests for molecular detection of infectious diseases in a format that permits testing to be performed wherever the need for timely and accurate information is most vital to disease surveillance and patient care. In addition to its own product development endeavors, the company offers custom microfluidics-enabled product design, development and production services on behalf of clients worldwide. For additional information please visit www.micronics.net.

About Seattle Children’s Research Institute

At the forefront of pediatric medical research, Seattle Children’s Research Institute has nine major centers, and is internationally recognized for advancing discoveries in cancer, genetics, immunology, pathology, infectious disease, injury prevention and bioethics. In its quest to cure childhood disease, the research institute brings discoveries to the bedside in partnership with Seattle Children’s Hospital and Seattle Children’s Hospital Foundation. Together they are Seattle Children’s, known for setting new standards in superior patient care for more than 100 years. Children’s serves as the primary teaching, clinical and research site for the Department of Pediatrics at the University of Washington School of Medicine, which consistently ranks as one of the best pediatric departments in the country. For more information visit www.seattlechildrens.org/research.

Press Relations Contact

It is very difficult to discover current and insightful best management practices from other technology companies our size. River Cities is very good about gathering and sharing that information in meaningful ways among their portfolio companies.

— Intradiem

Testimonial

River Cities has been a valuable partner to Univa UD. In addition to providing financial and business advice, River Cities has utilized their experience and contacts within our industry to help move our business forward. They have introduced us to key executives at customers, strategic partners and other Industry experts who has proved invaluable to our business. River Cities has also provided us with important strategic and operational input that has aided us in building a leadership position in our fast growing market.

— Univa UD

Testimonial

What makes River Cities a trusted and valued partner is their strategic guidance and support of management during the inevitable difficult periods. In my estimation this separates a good investor from a great one.

— Rob Morocco, CEO, OrthoScan, Inc.

Testimonial

River Cities history and expertise in working with early stage companies proved invaluable in the formative years of PerfectServe. While our strategy shifted to better meet market dynamics, the team at River Cities was always there as a source of encouragement and business development. They made strategic introductions to some of our earliest hospital clients, contributing significantly to our growth. The people at River Cities are creative, constructive and straightforward. I am grateful for the opportunity to work with them as my business partners.

— Terrell Edwards, CEO, PerfectServe, Inc.

Testimonial

River Cities Capital Funds is seasoned and it shows in how they add value to the business. The River Cities team has truly become part of our team, with a collaborative approach grounded in a clear understanding of what is important in our business - they do an excellent job of keeping us focused on what matters.

— John Filby, CEO, ISD Corporation

Testimonial

River Cities approached their investment in a way that made you feel like you had another positive resource. It was a true professional partnership with positive support and interaction. At the same time it is all about performance, and River Cities kept keenly aware of our business practices.

— Dennis Stripe, CEO, OrthoHelix

Testimonial

The River Cities team brings an excellent external perspective and network to our company. They are a perfect example of the value-added investor, an organization who provides experience, thoughts and assistance when asked but never forced. They offer a dialog based upon candor and integrity, delivered without the extra work, distraction or dissonance that can accompany an external investor.

— Stephen Wiehe, President & CEO, SciQuest, Inc.

Testimonial

River Cities has demonstrated great acumen in the presentation and marketing of the Company to others, whether assisting us in finding other investors or in attracting executive talent to the Company. In many respects, River Cities has been a model for savvy entrepreneur-VC collaboration.

— Robert A. Fisher, CEO, Foresight Corporation

Testimonial

River Cities demonstrated significant leadership for the Company's investor syndicate. They rolled up their sleeves and dug into the details, which enabled us to make good decisions based on facts and practical assumptions. Their grounded approach to identifying opportunities and overcoming challenges served management and the investors well.

— Mike Nazzaro, President, Nielson BuzzMetrics

Testimonial

River Cities has been extremely supportive - not only with their investment, but with their coaching on almost every aspect of our business. Put another way, River Cities Capital Funds represents a tremendous resource that comes in a very user-friendly package.

— Phil Gilmour, CEO, EVault, Inc.

Stay Updated

Stay connected by subscribing to our quarterly e-newsletter. Get the latest news and updates sent right to your inbox..

This form needs Javascript to display, which your browser doesn't support. Sign up here instead

ABOUT RIVER CITIES CAPITAL FUNDS

River Cities Capital Funds is one of the most active and experienced growth equity funds in healthcare and information technology. With over $500 million raised to date and more than 100 investments made, we have established ourselves as a preferred partner among the entrepreneurial and private equity communities.